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Structural and functional footprint of visual
snow syndrome
Christoph J. Schankin,1,2 Farooq H. Maniyar,2,3 Denise E. Chou,2,4 Michael Eller,2,5
Till Sprenger6 and Peter J. Goadsby2,7
Patients with visual snow syndrome suffer from a continuous pan-field visual disturbance, additional visual symptoms, tinnitus, and
non-perceptional symptoms. The pathophysiology of visual symptoms might involve dysfunctional visual cortex. So far, the extra-vis-
ual system has not been investigated. We aimed at identifying structural and functional correlates for visual and non-visual symptoms
in visual snow syndrome. Patients were compared to age- and sex-matched controls using 18F-2-fluoro-2-deoxy-D-glucose PET
(n = 20 per group) and voxel-based morphometry (n = 17 per group). Guided by the PET results, region of interest analysis was done
in voxel-based morphometry to identify structural-functional correspondence. Grey matter volume was assessed globally. Patients had
corresponding hypermetabolism and cortical volume increase in the extrastriate visual cortex at the junction of the right lingual and
fusiform gyrus. There was hypometabolism in the right superior temporal gyrus and the left inferior parietal lobule. Patients had grey
matter volume increases in the temporal and limbic lobes and decrease in the superior temporal gyrus. The corresponding structural
and functional alterations emphasize the relevance of the visual association cortex for visual snow syndrome. The broad structural
and functional footprint, however, confirms the clinical impression that the disorder extends beyond the visual system.
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Introduction
Patients with visual snow syndrome (VSS) suffer from a con-
tinuous visual disturbance consisting of visual snow and
additional visual symptoms: palinopsia, enhanced entoptic
phenomena, such as floaters and blue field entoptic
phenomenon, photophobia and impaired night vision
(Schankin et al., 2014a). The pathophysiology of the condi-
tion is poorly understood. The high co-morbidity with mi-
graine (Schankin et al., 2014b), a disorder of sensory
processing (Goadsby et al., 2017), suggests some patho-
physiological overlap. This is supported by recent imaging
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and electrophysiological data suggesting a dysfunction of
visual processing at the level of the visual association cortex
(Schankin et al., 2014b; Eren et al., 2018; Luna et al.,
2018). Treatment remains frustrating. Further, many
patients with VSS also suffer from non-visual complaints,
such as tinnitus, concentration problems, irritability, and
lethargy (Schankin et al., 2014a). This suggests alterations in
several extra-visual cortical areas, such as the auditory or
the limbic system.
The objective of this study was to improve our under-
standing of VSS by exploring brain areas that differ in struc-
ture, or function, or both, from controls. Specifically, we
sought to determine areas with corresponding structural and
functional alterations. In addition, we assessed brain metab-
olism and structure in an exploratory, voxel-wise manner.
These data have been presented in preliminary form [17th
Congress of the International Headache Society, Valencia
14–17 May 2015 (Schankin et al., 2015)]
Materials and methods
This prospective case-control study was carried out at a tertiary
headache centre after approval by the local ethics committee
(11-07431) and the radiation safety committee (58605-RU-04-
URH). All subjects gave written informed consent. Patients were
recruited via advertisements in social media with the support of
a self-help group on visual snow (Eye on Vision Foundation;
http://eyeonvision.org). Data on a subgroup of patients pre-
sented here (n = 17) have been published in a previous report
investigating solely hypermetabolism (Schankin et al., 2014b).
Participants
Eligibility was assessed during telephone interviews. Inclusion cri-
teria were black and white visual snow, i.e. dynamic, continuous,
tiny dots in the entire visual field lasting longer than 3 months,
with at least three additional visual symptoms (Schankin et al.,
2014a). Controls were matched for age and sex. Exclusion crite-
ria for controls were: presence of visual snow or any associated
visual symptoms, a history of migraine attacks more often than
once every 2 months, or of migraine aura (Headache
Classification Committee of the International Headache Society,
2018). Exclusion criteria for both groups were ophthalmological
pathologies other than refraction anomalies, any lifetime history
of intake of hallucinogenic drugs or recent (56 months) history
of intake of recreational drugs, age older than 50 years, contrain-
dications for PET or MRI, and pregnancy. Each subject under-
went a semi-structured interview focusing on visual symptoms,
migraine history including typical aura and general past medical
history. Standard questionnaires were used to assess potential de-
pression (PHQ-8) and anxiety (GAD-7) with clinically relevant
depression or anxiety being defined by a score of 49 (Lowe
et al., 2008; Kroenke et al., 2009).
Each patient had visual evoked potentials (standard pattern
reversal stimuli, monocular response, both eyes) and 18-channel
EEG (standard international 10-20 electrode placement).
Imaging
On the scanning day, each subject had a fasting period of at
least 6 h. High-resolution T1-weighted anatomical MRI [axial
T1, 3D IRSPGR (inversion recovery spoiled gradient echo), repe-
tition time 7.252, echo time 1.6, inversion time 400, 180 images
acquired, slice thickness 1 mm] was performed on a General
Electric Signa HDxT 3.0 T scanner (GE Healthcare). In three
patients with visual snow, a slice thickness of 1.5 mm was
applied instead because of a technical problem on the scanning
day. Afterwards, the subjects were injected with 370 MBq of
18F-2-fluoro-2-deoxy-D-glucose (FDG) as an intravenous bolus
and were instructed to rest in a darkened room for 45 min with
eyes closed. PET scans were acquired using a GE Discovery
VCT PET/CT scanner (GE Healthcare) in 3D mode with septa
retracted. A low-mA CT scan prior to the PET was used for at-
tenuation correction. Scatter correction was also applied based
on the CT-based attenuation map. During scanning, all subjects
had their eyes closed and were instructed not to fall asleep. The
scan duration was 15 min. One static frame was acquired. We
visually observed the patient head motion during the scan. In
our data, no significant blurring in reconstructed images was
noted that might be caused by significant head motion. Motion
correction was not applied. PET images were reconstructed
using the manufacturer-provided 3D iterative reconstruction
into 47 image planes (separation 3.27 mm) and into a
128  128 image matrix (pixel size: 2.1  2.1 mm2). These
images were used as input for the Statistical Parametric
Mapping (SPM) analysis. The image pixel values in activity con-
centration (Bq/ml) were used, instead of converting them to
standardized uptake values (SUVs).
Analysis
The structural MRI data were first co-registered to the PET data
using SPM8 (Wellcome Department of Imaging Neuroscience,
http://www.fil.ion.ucl.ac.uk/spm) followed by automated seg-
mentation as well as stereotactic normalization to MNI
(Montreal Neurological Institute) space.
The parameters obtained from this step were applied to normal-
ize stereotactically the PET images. The final resliced voxel size of
the PET images was 2  2  2 mm3. The PET images were
smoothed with a Gaussian kernel (full-width at half-maximum of
12 mm). The VSS patient group was compared to controls using a
two-sample t-test with masking of non-brain tissue (whole brain
explicit mask generated with WFU PickAtlas, Advanced
Neuroscience Imaging Research Laboratory, Department of
Radiology of Wake Forest University School of Medicine, http://
fmri.wfubmc.edu/) using proportional scaling. Statistical signifi-
cance was assumed for areas with P50.001, uncorrected for
multiple comparisons.
For voxel-based morphometry (VBM), only patients who had
MRI with slice thickness of 1 mm were analysed. The VBM
toolbox for SPM8 (VBM8, version 435, http://dbm.neuro.uni-
jena.de/vbm/) was used to normalize semi-automatically (modu-
lated normalization) and to segment the MRI data into grey
matter, white matter and CSF using standard parameters. Grey
matter images were smoothed with a kernel with 8mm full-
width at half-maximum. The smoothed grey matter images were
compared between VSS patients and controls using standard
parameters.
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For our primary research question, we assessed structural
(VBM)-functional (PET) correspondence of abnormalities in
VSS patients. The statistical peak coordinates from the PET clus-
ters were used to guide region of interest analysis in VBM. For
this purpose, spherical regions of interest with a radius of
10 mm (Carreiras et al., 2009) were generated around the PET
peak coordinate clusters as explicit mask using the MarsBaR
region of interest toolbox for SPM (Brett et al., 2002). The
VSS patient group was compared to controls using a two-sample
t-test with correction for multiple comparisons [familywise error
(FWE) rate of P50.05 on cluster level).
For the secondary research question, an exploratory whole
brain analysis was performed (two-sample t-test, P50.001, un-
corrected for multiple comparisons).
SPSS (v20, IBM Corp., Armonk, New York, USA) was used
for analysis of non-imaging data. Standard descriptive statistics
were applied. Where appropriate, data are presented as mean ±
standard deviation (SD). Nominal data were compared using
chi-square test, continuous data using t-test. Significance was
defined by P50.05.
Data availability
Anonymized data will be shared by reasonable request from any
qualified investigator.
Results
Participant demographics
Of 20 patients with black and white visual snow and at least
three additional visual symptoms (11 female, 18 right-
handed, mean age ± SD = 31± 7 years), nine had had visual
snow for as long as they could remember. Mean age of
onset in the remaining was 24±8 years. Sixteen (80%) had
a history of migraine. Five of those had migraine with typ-
ical aura (Headache Classification Committee of the
International Headache Society, 2018), and one had mi-
graine aura without headache (Table 1). Sixteen (80%)
patients suffered from concentration problems, 11 (55%)
from irritability, 10 (50%) from tinnitus, and eight (40%)
from lethargy. Past medical history was otherwise unremark-
able. According to the questionnaires, one patient had de-
pression and anxiety, one anxiety only, and one depression
only. Reports of an ophthalmological exam were available
in all patients (all had normal fundoscopy, automated visual
fields abnormal in one with generalized reduced sensitivity,
best corrected visual acuity normal in all except for 20/25 bi-
lateral in one and 20/20-2 left in another). Visual evoked
potentials (P100 latency and N75-P100 amplitude) and EEG
were normal in all patients.
The 20 controls had the same age and sex distribution [11
female, 18 right-handed, 30± 7 years, t(38) = 0.25, P = 0.81
for age], but differed significantly from patients in respect of
history of aura [exclusion criterion, v2(1) = 7.06, P = 0.02]
and history of migraine [no control subject had migraine,
v2(1) = 26.67, P50.001]. One control subject had anxiety,
another one had depression [v2(1) = 0.36, P = 1.00].
Imaging
In patients with VSS, FDG PET demonstrated hypermetabo-
lism in the right lingual gyrus in Brodmann area (BA) 19.
For VBM, three patients had to be excluded due to slice
thickness of 1.5 mm in MRI. Guided by the metabolic data,
VBM identified increased grey matter volume in the adjacent
lingual gyrus-fusiform gyrus junction (maximum of VBM at
MNI: x = 26, y = –69, z = –14, Z = 3.46, P = 0.03 FWE-
corrected on cluster-level, kE = 12). In FDG PET, there was
hypometabolism in the right superior temporal gyrus (BA
22) and the left inferior parietal lobule (BA 40), without cor-
responding changes in grey matter volume (Fig. 1 and
Table 2).
Using a whole-brain analysis, VBM identified additional
grey matter volume increases in VSS that did not co-localize
with PET changes in the right middle temporal gyrus, the
right parahippocampal gyrus, the left superior temporal
gyrus as well as the right anterior cingulate cortex. Grey
matter decreases were found in the left superior temporal
gyrus (Fig. 2 and Table 2).
Discussion
From a clinical perspective, VSS presents with debilitating
visual as well as non-visual symptoms. Using two different
brain imaging modalities, FDG PET and VBM, this study
assessed brain metabolism and grey matter volume changes
as surrogate parameters for brain function and structure in
patients with VSS.
The corresponding hypermetabolism and cortical volume
increase in the extrastriate visual cortex at the junction of
the right lingual and fusiform gyrus is consistent with a pre-
vious smaller group-size functional study (Schankin et al.,
2014b) and electrophysiological evidence (Eren et al., 2018).
It confirms at a structural level the importance of this region
for VSS. Previous studies have shown involvement of the lin-
gual, or fusiform gyrus, or both, in colour perception (Rizzo
et al., 1992), face (Kanwisher et al., 1997), and shape recog-
nition (Corbetta et al., 1991) supporting that this region is
relevant for complex visual processing.
Palinopsia, i.e. the inability to suppress the just-seen
(Critchley, 1951) is a defining associated symptom in
patients with VSS (Schankin et al., 2014a), and was present
in 17 patients of this study. Palinopsia can be found in occi-
pito-parietal lesions (Gersztenkorn and Lee, 2015). The
hypometabolism in the inferior parietal lobule found in our
study might therefore represent a biological correlate of
patients’ palinopsia. This is supported by a case report of a
patient who had palinopsia with a haematoma in the angu-
lar gyrus of the inferior parietal lobule (Hayashi et al.,
2002). Palinacousis, i.e. the prolonged perception of the just-
heard, has been associated with the inferior parietal lobule
(Mohamed et al., 2012) suggesting that this region might be
important even for the suppression of the just-perceived in
general, independent of the sensory modality.
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Further, metabolic and grey matter volume alterations
were found in the temporal lobe, the limbic system and the
parietal lobe. These areas are not typically associated with
visual processing. Hypothetically, this functional and struc-
tural footprint might reflect the clinical observation of VSS
symptoms extending beyond the visual system (Schankin
et al., 2014a). Tinnitus, for example, is a relevant non-visual
symptom in VSS (Schankin et al., 2014a) and was present in
50% of our patients, potentially reflecting the acoustic
equivalent of visual snow. Recent evidence suggests that the
inferior parietal lobule (Lv et al., 2016) and the superior
temporal gyrus (Liu et al., 2018) might both be involved in
the development of tinnitus. In our patients, the hypometab-
olism of both regions and the altered grey matter volume in
the superior temporal gyrus might therefore represent a
pathophysiological correlate of tinnitus.
In clinical practice, patients further report non-perceptional
symptoms, such as problems concentrating, irritability, and
lethargy (Schankin et al., 2014a). This is sometimes mistaken
as an underlying or causative psychiatric or psychosomatic
condition. However, these symptoms might suggest involve-
ment of limbic or temporal structures in VSS. The hypome-
tabolism of the superior temporal gyrus found in our study is
in agreement with its role for irritability (Besteher et al.,
2017) and for thought suppression of pain (Chehadi et al.,
2018). The latter study further demonstrated involvement of
the middle temporal gyrus in cognitive pain control, an area
that also exhibited grey matter volume increase in VSS.
These areas might be correlates of the inability to suppress or
control the continuous visual perception in VSS.
A limitation of our study is that there was an asymmetric
distribution of co-morbid migraine and typical migraine
aura in both groups. Two previous studies have investigated
migraine and migraine aura using FDG PET, and neither
demonstrated hypermetabolism in the visual association cor-
tex (Aurora et al., 2007; Kim et al., 2010). With respect to
grey matter volume, paediatric patients with migraine with
aura demonstrated increased grey matter volume in the fusi-
form gyrus contralateral to our patients with VSS (i.e. left)
(Rocca et al., 2014). In patients with chronic migraine,
Coppola et al. (2017) found grey matter volume reductions
in the left middle temporal gyrus and the visual association
cortex, areas of grey matter volume increase in VSS.
Similarly, Riederer et al. (2012) demonstrated grey matter
volume decrease in medication overuse headache in the an-
terior cingulate cortex (Riederer et al., 2012), an area show-
ing grey matter volume increase in VSS. One study found
grey matter increases in migraineurs in the middle temporal
gyrus, but no other overlap with our results (Palm-Meinders
et al., 2017). The majority of studies in migraine did not
demonstrate grey matter volume increases in patients
(Schmidt-Wilcke et al., 2008; Valfre et al., 2008;
Table 1 Demographics, visual symptoms and migraine history in the study population with visual snow syndrome
Patient Age Age at
onset
Sex Visual symptoms Migraine Aura
BW Palinopsia Entoptic phenomena Nyctalopia Photo-
phobia
Trailing After
images
Floaters Photopsia BFEP Self-light
VS1 35 32 M 1 0 1 0 1 1 0 1 1 0 1
VS2 39 a F 1 0 0 1 0 1 1 1 1 1 0
VS3 24 a F 1 1 1 1 1 1 1 0 0 0 0
VS4 37 20 F 1 0 1 0 0 1 0 0 1 1 1
VS5 29 24 F 1 1 1 1 1 1 1 1 1 1 0
VS6 23 17 F 1 0 1 1 0 0 1 1 1 1 0
VS7 40 39 F 1 1 1 1 0 0 0 1 1 0 0
VS8 29 28 M 1 0 1 1 0 1 0 0 0 1 1
VS9 36 34 F 1 0 1 0 1 1 1 1 1 1 1
VS10 32 24 M 1 1 1 1 0 1 1 1 0 1 1
VS11 35 a F 1 1 1 0 0 0 1 1 1 1 0
VS12 24 a F 1 0 1 1 1 1 1 1 0 1 1
VS13 25 a M 1 1 0 1 0 1 0 1 1 1 0
VS14 35 a M 1 0 0 1 1 0 1 1 0 1 0
VS15 47 a F 1 1 1 0 0 1 1 1 0 1 0
VS16 22 13 M 1 0 1 0 0 1 0 1 1 1 0
VS17 21 20 M 1 1 0 1 0 0 1 1 1 1 0
VS18 27 a F 1 1 1 1 0 1 0 1 0 1 0
VS19 21 a M 1 1 1 1 0 1 0 1 0 1 0
VS20 33 16 M 1 0 0 1 0 1 0 1 1 0 0
aPatients recall having visual snow as for long as they can remember.
0 = absent; 1 = present; Aura = history of typical migraine aura; BW = black and white visual snow; BFEP = blue field entoptic phenomenon; migraine = history of migraine with or
without aura (depending on the presence of aura); nyctalopia = impaired night vision; photopsia = random flashes of light, mainly in the periphery and without mechanical stimula-
tion of the retina; self-light of the eye = patients perceive coloured clouds or waves when briefly closing their eyes.
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Figure 1 Differences in brain metabolism between patients with VSS and controls. When compared to controls, patients with VSS
demonstrated hypermetabolism in FDG PET (red) and a corresponding increase of grey matter volume as determined by VBM (yellow) at the
junction of the lingual and fusiform gyrus on the right, both in Brodmann area (BA) 19 (A–C). VSS patients showed additional areas of hypome-
tabolism in the right superior temporal gyrus (BA 22, D1) and left inferior parietal lobule (BA 40, D2) without corresponding alterations in grey
matter volume. PET statistical parametric maps at a threshold of P5 0.001 uncorrected for multiple comparisons are overlaid on a normalized
standard T1-weighted MRI. The VBM map was obtained using a 10-mm sphere as an explicit mask around the maximum from significant PET clus-
ters and thus represents only a part of the grey matter alterations shown in Fig. 2 (threshold P5 0.05, family wise error rate on cluster level).
VS = visual snow.
Table 2 Coordinates of metabolic and structural differences between patients with visual snow syndrome and
controls
MNI kE Z-score P-value Side Lobe Gyrus BA
x y z
PET
VS 4 C 20 –68 –7 49 3.4 0 Right Occipital Lingual 19
VS 5 C 66 4 –9 309 3.68 0 Right Temporal Superior temporal 22
–64 –32 21 58 3.57 0 Left Parietal Inferior parietal lobule 40
VBM
VS 4 C 26 –69 –15 29 3.52 0 Right Temporal Fusiform 19
54 –27 –15 159 4.11 0 Right Temporal Middle temporal 21
20 –24 –23 21 3.28 0.001 Right Limbic Parahippocampal 35
–50 –15 –14 71 3.41 0 Left Temporal Superior temporal 22
15 35 7 57 3.28 0.001 Right Limbic Anterior cingulate 32
VS 5 C –54 5 1 30 3.32 0 Left Temporal Superior temporal 22
Metabolic (FDG PET, n = 20 per group) and structural (VBM, n = 17 per group) changes in patients with visual snow syndrome in comparison to age and sex matched controls.
Guided by the metabolic data, small volume correction using a sphere with 10-mm radius around the peak of metabolic activity (VS 4 C in PET, MNI 20 – 68 – 7) identified corre-
sponding increased grey matter volume (VS 4 C in VBM, FWE corrected P = 0.03 on cluster level, peak at MNI 26 – 69 – 14, data not shown in table).
BA = Brodmann area; kE = number of contiguous voxels with Z-score 4 3.3 (P5 0.001); MNI = standard space as defined by the Montreal Neurological Institute; VS 5 C = visual
snow group is metabolically less active (FDG PET) or has less grey matter volume (VBM) than control group; VS 4 C = visual snow group is metabolically more active (FDG PET)
or has larger grey matter volume (VBM) than control group.
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Neeb et al., 2017). In patients with migraine with aura,
Hougaard et al. (2015) found differences in cortical thick-
ness in the inferior frontal lobe that were not altered in
patients with VSS. The same group assessed response to vis-
ual stimulation in patients with strictly side-locked migraine
aura. Compared to the contralateral side, there was an
increased response in the inferior parietal lobule on the aura
side (Hougaard et al., 2014). In VSS, we demonstrated
hypometabolism in the same area. A bias from the higher
frequency of co-morbid migraine aura in the VSS group,
however, is unlikely in the view of only six patients having
migraine aura that was side-locked in none. In summary, the
metabolic and structural profile found in our study for VSS
does not substantially overlap with the profile of migraine. It
is therefore unlikely that our findings are a consequence of
co-morbid migraine or aura rather than VSS.
Another limitation is that the power of the study was too
low for subgroup analyses looking specifically for the areas
responsible for individual additional symptoms, such as pali-
nopsia or tinnitus.
The structural and functional footprint of VSS suggests
dysfunction of several brain areas involved in visual, audi-
tory, emotional, and cognitive processing. The co-localizing
structural and functional alteration in the occipital lobe sup-
ports the idea that the disturbance causing visual symptoms
might be located in the visual association cortex and not in
the primary visual cortex. The alterations in the other areas
shown in this study are first imaging evidence that VSS is in-
deed a complex clinical syndrome that affects more than just
the visual system. It is in line with the various complaints
stated by patients in daily clinical practice and suggests that
multimodal and multidisciplinary treatment might be useful,
Figure 2 Grey matter volume differences between patients with VSS and controls. Using VBM, we observed grey matter volume
increases (visual snow 4 control) in the right fusiform gyrus (A), the right middle temporal gyrus (B), the right parahippocampal gyrus (C), the
left superior temporal gyrus (D) as well as the right anterior cingulate cortex (F) in patients with visual snow syndrome. Grey matter decreases
were found in the left superior temporal gyrus (E). VBM statistical parametric maps at a threshold of P5 0.001 uncorrected for multiple compar-
isons are overlaid on a normalized standard T1-weighted MRI. VS = visual snow.
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in addition to a potential pharmacological treatment of the
visual symptoms. Clinical profiling of visual, auditory, emo-
tional, and cognitive functions might be important for better
understanding the interactions between these domains.
Correlating symptoms with neurobiology secure the identifi-
cation of visual snow as an entity and offer directions for
potential therapeutic developments for this currently very
challenging to manage disorder.
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